Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis.
暂无分享,去创建一个
M. Eberl | J. Köhl | M. Labéta | N. Topley | D. Fraser | A. Kift-Morgan | C. Colmont | A. Raby
[1] M. Teixeira,et al. Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis , 2015, PloS one.
[2] Taro Kawai,et al. Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..
[3] H. Anders,et al. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. , 2014, Journal of the American Society of Nephrology : JASN.
[4] David W. Johnson,et al. Clinical Causes of Inflammation in Peritoneal Dialysis Patients , 2014, International journal of nephrology.
[5] Samy Lamouille,et al. Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.
[6] W. Parks,et al. Diverse functions of matrix metalloproteinases during fibrosis , 2014, Disease Models & Mechanisms.
[7] P. Taylor,et al. Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation , 2014, Immunity.
[8] M. Dorval,et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. , 2013, Journal of the American Society of Nephrology : JASN.
[9] A. Boulares,et al. PDZK1 Is a Novel Factor in Breast Cancer That Is Indirectly Regulated by Estrogen through IGF-1R and Promotes Estrogen-Mediated Growth , 2013, Molecular Medicine.
[10] R. Schwabe,et al. Regulation of wound healing and organ fibrosis by toll-like receptors. , 2013, Biochimica et biophysica acta.
[11] M. Lotze,et al. Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14 , 2013, Molecular Medicine.
[12] Judith E. Hall,et al. Targeting the TLR Co-Receptor CD14 with TLR2-Derived Peptides Modulates Immune Responses to Pathogens , 2013, Science Translational Medicine.
[13] P. Walsh,et al. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. BioTechniques 10(4): 506-13 (April 1991). , 2013, BioTechniques.
[14] R Higuchi,et al. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. , 2013, BioTechniques.
[15] Shirong Cao,et al. The Potential Role of HMGB1 Release in Peritoneal Dialysis-Related Peritonitis , 2013, PloS one.
[16] J. Lambris,et al. The Role of Properdin in Zymosan- and Escherichia coli-Induced Complement Activation , 2012, The Journal of Immunology.
[17] T. Chan,et al. Pathophysiological Changes to the Peritoneal Membrane during PD-Related Peritonitis: The Role of Mesothelial Cells , 2012, Mediators of inflammation.
[18] Y. Tomino. Mechanisms and interventions in peritoneal fibrosis , 2012, Clinical and Experimental Nephrology.
[19] K. Mills,et al. TLR based therapeutics. , 2011, Current opinion in pharmacology.
[20] C. Fielding,et al. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] J. Köhl,et al. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2 , 2011, European journal of immunology.
[22] Grace Y Chen,et al. Sterile inflammation: sensing and reacting to damage , 2010, Nature Reviews Immunology.
[23] S. Akira,et al. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.
[24] O. Levy,et al. TLR2 Mediates Recognition of Live Staphylococcus epidermidis and Clearance of Bacteremia , 2010, PloS one.
[25] John D Lambris,et al. Microbial Hijacking of Complement–Toll-Like Receptor Crosstalk , 2010, Science Signaling.
[26] C. Mackay,et al. The C5a Receptor (C5aR) C5L2 Is a Modulator of C5aR-mediated Signal Transduction* , 2009, Journal of Biological Chemistry.
[27] J. Coombes,et al. Cardiovascular disease in peritoneal dialysis patients. , 2009, Panminerva medica.
[28] G. Wolf,et al. TGF-beta and fibrosis in different organs - molecular pathway imprints. , 2009, Biochimica et biophysica acta.
[29] Simon A. Jones,et al. Soluble TLR2 Reduces Inflammation without Compromising Bacterial Clearance by Disrupting TLR2 Triggering1 , 2009, The Journal of Immunology.
[30] S. Akira,et al. Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4 , 2009, Proceedings of the National Academy of Sciences.
[31] H. Wagner,et al. TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice , 2008, The Journal of experimental medicine.
[32] H. Wagner,et al. TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice , 2008, The Journal of Experimental Medicine.
[33] H. Heine,et al. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. , 2008, Immunobiology.
[34] C. Mackay,et al. Functional roles for C5a receptors in sepsis , 2008, Nature Medicine.
[35] John D Lambris,et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. , 2007, Blood.
[36] R. Coffman,et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.
[37] C. McKerlie,et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a , 2007, Nature.
[38] J. Pugin,et al. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. , 2007, Blood.
[39] L. Wakefield,et al. IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent , 2004, The Journal of Immunology.
[40] Andrew Leask,et al. TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] K. Lai,et al. Regulation of complement C3 and C4 synthesis in human peritoneal mesothelial cells by peritoneal dialysis fluid , 2004, Clinical and experimental immunology.
[42] J. V. Sarma,et al. Regulatory role of C5a in LPS‐induced IL‐6 production by neutrophils during sepsis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[43] M. Grigorov,et al. Soluble Forms of Toll-Like Receptor (TLR)2 Capable of Modulating TLR2 Signaling Are Present in Human Plasma and Breast Milk , 2003, The Journal of Immunology.
[44] Peter A. Ward,et al. Novel strategies for the treatment of sepsis , 2003, Nature Medicine.
[45] A. Ortiz,et al. Inhibition of Caspases Improves Bacterial Clearance in Experimental Peritonitis , 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[46] S. Ju,et al. Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors1 , 2001, The Journal of Immunology.
[47] N. Di Paolo,et al. Morphological aspects of peritoneal sclerosis. , 2001, Journal of nephrology.
[48] T. S. Wilkinson,et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. , 2001, Immunity.
[49] S. Akira,et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5 , 2001, Nature.
[50] T. Chan,et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] S. Akira,et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.
[52] P. Ferrara,et al. Soluble CD14 acts as a negative regulator of human T cell activation and function , 1999, European Journal of Immunology.
[53] M. Daha,et al. Complement in Serum and Dialysate in Children on Continuous Ambulatory Peritoneal Dialysis , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[54] P. Ferrara,et al. The two soluble forms of the lipopolysaccharide receptor, CD14: Characterization and release by normal human monocytes , 1994, European journal of immunology.
[55] K. Schärer,et al. Peritoneal morphology in children treated by continuous ambulatory peritoneal dialysis , 1992, Pediatric Nephrology.
[56] J. S. Cameron,et al. Clinical applications of crossed immunoelectrophoresis to the study of complement activation. , 1987, Journal of clinical & laboratory immunology.
[57] H. Verbrugh,et al. The role of Staphylococcus aureus cell-wall peptidoglycan, teichoic acid and protein A in the processes of complement activation and opsonization. , 1979, Immunology.
[58] T. Espevik,et al. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. , 2008, Advances in experimental medicine and biology.
[59] N. Di Paolo,et al. Pathophysiology and morphological clinical correlation in experimental and peritoneal dialysis-induced peritoneal sclerosis. , 2000, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.
[60] G. Young,et al. Complement activation during CAPD. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.